Coronavax
Coronavax, with a valuation of $10 million, is raising funds on PicMii. The company is developing a new therapeutic to treat the symptoms of long COVID. Coronavax’s drug, CVAX-001, uses ideas from cancer immunotherapy to teach the immune system to attack the infected cells and reduce inflammation through mucosal immunity. The drug will be delivered by nasal spray and will eliminate the virus directly at the source. Bruce Lyday and Adam Ruskin founded Coronavax in January 2024. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1.24 million. The campaign proceeds will be used for research and development, salaries, and legal and administrative expenses.
Investment Overview
Raised: $3,758
Deal Terms
Total Commitments ($USD)
- Platform
- PicMii
- Start Date
- 09/16/2024
- Close Date
- 12/30/2024
$10,000
$1,235,000
$250
Equity - Common
Pre-Seed
RegCF
$5.00
$10,000,000
Company & Team
Company
- Year Founded
- 2024
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $655,000
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | PicMii | $10,000,000 | $3,758 | Equity - Common | Active | RegCF |